(Q35177585)

6 August 2017

1 reference

title

T cell targeted immune enhancement yields effective T cell adjuvants (English)

1 reference

6 August 2017

Paul H Naylor

1

1 reference

6 August 2017

John W Hadden

series ordinal

2

1 reference

6 August 2017

publication date

1 August 2003

1 reference

International Immunopharmacology

6 August 2017

published in

1 reference

6 August 2017

volume

3

1 reference

6 August 2017

issue

8

1 reference

6 August 2017

page(s)

1205-1215

1 reference

Recent developments in adjuvants for vaccines against infectious diseases

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Towards the rational design of Th1 adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Immunological concepts of vaccine adjuvant activity

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

What are the limits of adjuvanticity?

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Immunomodulators and delivery systems for vaccination by mucosal routes.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Immunosenescence and infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Clinical cancer vaccine trials

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Adjuvants--a balance between toxicity and adjuvanticity

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Prospects for the development of new vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

1 reference

7 January 2021

Toll-like receptors as adjuvant receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

The plasticity of dendritic cell responses to pathogens and their components

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

The role of chemokines in linking innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

The prospects for cancer gene therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Developing non-viral DNA delivery systems for cancer and infectious disease

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Antigen-specific humoral and cellular immune responses can be modulated in rhesus macaques through the use of IFN-gamma, IL-12, or IL-18 gene adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Uses of granulocyte-macrophage colony-stimulating factor in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

The immunopharmacology of head and neck cancer: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Interleukins and contrasuppression induce immune regression of head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Development of dendritic-cell based prostate cancer vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Augmentation of influenza antibody response in elderly men by thymosin alpha one. A double-blind placebo-controlled clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Effect of oral levamisole supplementation to hepatitis B vaccination on the rate of immune response in chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Enhancement of in vitro lipopolysaccharide-stimulated interleukin-1 production by levamisole

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Levamisole induces interleukin-18 and shifts type 1/type 2 cytokine balance

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Purine enzymes and immune function

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

The use of mycophenolate mofetil in transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

A nucleoside-nucleotide mixture and its components increase lymphoproliferative and delayed hypersensitivity responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Potentiation of immune responses in mice by a new inosine derivative--methyl inosine monophosphate (MIMP)

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Immunopharmacologic properties of inosine 5'-methyl monophosphate (MIMP).

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Methyl inosine monophosphate: a potential immunotherapeutic for early human immunodeficiency virus (HIV) infection

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

Methyl inosine monophosphate (MIMP) augments T-lymphocyte mitogen responses and reverses various immunosuppressants

1 reference

https://api.crossref.org/works/10.1016%2FS1567-5769%2803%2900025-0

7 January 2021

10.1016/S1567-5769(03)00025-0

Identifiers

DOI

1 reference

6 August 2017

1 reference